Once-Daily Dosing of Delayed-Release Oral Mesalamine (400-mg Tablet) Is as Effective as Twice-Daily Dosing for Maintenance of Remission of Ulcerative Colitis
- 1 April 2010
- journal article
- research article
- Published by Elsevier BV in Gastroenterology
- Vol. 138 (4), 1286-1296.e3
- https://doi.org/10.1053/j.gastro.2009.12.054
Abstract
No abstract availableKeywords
Funding Information
- Procter and Gamble
This publication has 33 references indexed in Scilit:
- Oral 5-ASA Therapy in Ulcerative ColitisJournal of Clinical Gastroenterology, 2008
- The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro‐drugs used in the management of ulcerative colitisAlimentary Pharmacology & Therapeutics, 2002
- Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitisGastroenterology, 1998
- An Oral Preparation of Mesalamine as Long-Term Maintenance Therapy for Ulcerative ColitisAnnals of Internal Medicine, 1996
- Oral Mesalamine (Asacol) for Mildly to Moderately Active Ulcerative ColitisAnnals of Internal Medicine, 1991
- Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis.Gut, 1988
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987
- Azodisal sodium in the treatment of ulcerative colitisGastroenterology, 1986
- Adverse Reactions during Salicylazosulfapyridine Therapy and the Relation with Drug Metabolism and Acetylator PhenotypeNew England Journal of Medicine, 1973
- Salazopyrin, a new sulfanilamide preparation. A. Therapeutic Results in Rheumatic Polyarthritis. B. Therapeutic Results in Ulcerative Colitis. C. Toxic Manifestations in Treatment with Sulfanilamide Preparations.Acta Medica Scandinavica, 1942